- Home
- NKTX vs FLC Comparison
NKTX vs FLC Comparison
Compare NKTX & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- FLC
- Stock Information
- Founded
- NKTX 2015
- FLC 2003
- Country
- NKTX United States
- FLC United States
- Employees
- NKTX N/A
- FLC N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- NKTX Health Care
- FLC Finance
- Exchange
- NKTX Nasdaq
- FLC Nasdaq
- Market Cap
- NKTX 170.8M
- FLC 176.2M
- IPO Year
- NKTX 2020
- FLC N/A
- Fundamental
- Price
- NKTX $2.47
- FLC $16.85
- Analyst Decision
- NKTX Strong Buy
- FLC
- Analyst Count
- NKTX 5
- FLC 0
- Target Price
- NKTX $15.20
- FLC N/A
- AVG Volume (30 Days)
- NKTX 1.5M
- FLC 37.8K
- Earning Date
- NKTX 11-07-2024
- FLC 01-01-0001
- Dividend Yield
- NKTX N/A
- FLC 6.64%
- EPS Growth
- NKTX N/A
- FLC N/A
- EPS
- NKTX N/A
- FLC N/A
- Revenue
- NKTX N/A
- FLC N/A
- Revenue This Year
- NKTX N/A
- FLC N/A
- Revenue Next Year
- NKTX N/A
- FLC N/A
- P/E Ratio
- NKTX N/A
- FLC N/A
- Revenue Growth
- NKTX N/A
- FLC N/A
- 52 Week Low
- NKTX $2.08
- FLC $12.62
- 52 Week High
- NKTX $16.24
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- NKTX 50.49
- FLC 55.43
- Support Level
- NKTX $2.19
- FLC $16.46
- Resistance Level
- NKTX $2.70
- FLC $16.89
- Average True Range (ATR)
- NKTX 0.15
- FLC 0.23
- MACD
- NKTX 0.03
- FLC 0.02
- Stochastic Oscillator
- NKTX 54.90
- FLC 74.58
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.